KPRX Valuation
Kiora Pharmaceuticals Inc
$
2.730
- Overview
- Forecast
- Valuation
- Earnings
KPRX Relative Valuation
KPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KPRX is overvalued; if below, it's undervalued.
Historical Valuation
Kiora Pharmaceuticals Inc (KPRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.44 is considered Undervalued compared with the five-year average of -1.23. The fair price of Kiora Pharmaceuticals Inc (KPRX) is between 3.46 to 17.44 according to relative valuation methord. Compared to the current price of 2.62 USD , Kiora Pharmaceuticals Inc is Undervalued By 24.22%.
Relative Value
Fair Zone
3.46-17.44
Current Price：2.62
24.22%
Undervalued
-0.94
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Kiora Pharmaceuticals Inc. (KPRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.76
EV/EBIT
Kiora Pharmaceuticals Inc. (KPRX) has a current EV/EBIT of 0.76. The 5-year average EV/EBIT is -0.06. The thresholds are as follows: Strongly Undervalued below -2.85, Undervalued between -2.85 and -1.45, Fairly Valued between 1.34 and -1.45, Overvalued between 1.34 and 2.73, and Strongly Overvalued above 2.73. The current Forward EV/EBIT of 0.76 falls within the Historic Trend Line -Fairly Valued range.
2.43
PS
Kiora Pharmaceuticals Inc. (KPRX) has a current PS of 2.43. The 5-year average PS is 4.41. The thresholds are as follows: Strongly Undervalued below -12.81, Undervalued between -12.81 and -4.20, Fairly Valued between 13.02 and -4.20, Overvalued between 13.02 and 21.62, and Strongly Overvalued above 21.62. The current Forward PS of 2.43 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Kiora Pharmaceuticals Inc. (KPRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.16. The thresholds are as follows: Strongly Undervalued below -0.74, Undervalued between -0.74 and -0.45, Fairly Valued between 0.13 and -0.45, Overvalued between 0.13 and 0.42, and Strongly Overvalued above 0.42. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Kiora Pharmaceuticals Inc. (KPRX) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.38. The thresholds are as follows: Strongly Undervalued below -2.11, Undervalued between -2.11 and -1.25, Fairly Valued between 0.49 and -1.25, Overvalued between 0.49 and 1.36, and Strongly Overvalued above 1.36. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Kiora Pharmaceuticals Inc (KPRX) has a current Price-to-Book (P/B) ratio of 0.41. Compared to its 3-year average P/B ratio of 0.45 , the current P/B ratio is approximately -8.96% higher. Relative to its 5-year average P/B ratio of 0.97, the current P/B ratio is about -57.67% higher. Kiora Pharmaceuticals Inc (KPRX) has a Forward Free Cash Flow (FCF) yield of approximately -85.38%. Compared to its 3-year average FCF yield of -87.71%, the current FCF yield is approximately -2.65% lower. Relative to its 5-year average FCF yield of -85.18% , the current FCF yield is about 0.23% lower.
0.41
P/B
Median3y
0.45
Median5y
0.97
-86.02
FCF Yield
Median3y
-87.71
Median5y
-85.18
Competitors Valuation Multiple
The average P/S ratio for KPRX's competitors is 1.41, providing a benchmark for relative valuation. Kiora Pharmaceuticals Inc Corp (KPRX) exhibits a P/S ratio of 2.43, which is 71.82% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of KPRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KPRX in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Kiora Pharmaceuticals Inc (KPRX) currently overvalued or undervalued?
Kiora Pharmaceuticals Inc (KPRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.44 is considered Undervalued compared with the five-year average of -1.23. The fair price of Kiora Pharmaceuticals Inc (KPRX) is between 3.46 to 17.44 according to relative valuation methord. Compared to the current price of 2.62 USD , Kiora Pharmaceuticals Inc is Undervalued By 24.22% .
What is Kiora Pharmaceuticals Inc (KPRX) fair value?
How does KPRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Kiora Pharmaceuticals Inc (KPRX) as of Aug 23 2025?
What is the current FCF Yield for Kiora Pharmaceuticals Inc (KPRX) as of Aug 23 2025?
What is the current Forward P/E ratio for Kiora Pharmaceuticals Inc (KPRX) as of Aug 23 2025?